MCID: INT079
MIFTS: 51

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 52 6 15 17 71
Cholangiocarcinoma 43 71
Peripheral Intrahepatic Cholangiocarcinoma 71
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
MeSH 43 D018281
NCIt 49 C35417
SNOMED-CT 67 109842005
ICD10 32 C22.1
UMLS 71 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 52 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice , abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CCAT1 (Colon Cancer Associated Transcript 1), and among its related pathways/superpathways are mTOR signaling pathway (KEGG) and Central carbon metabolism in cancer. The drugs Celecoxib and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 750, show less)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 35.0 KRT7 IDH1
2 sarcomatous intrahepatic cholangiocarcinoma 34.9 KRT7 KRT19 AFP
3 klatskin's tumor 33.5 KRT7 KRT19 APC AFP
4 cholangiocarcinoma 33.2 TUG1 TP53 RASGEF1A MUC4 KRT7 KRT19
5 adenocarcinoma 31.7 TP53 MUC4 KRT7 KRAS FGFR2 APC
6 adenoma 31.4 TP53 KRT7 KRAS APC
7 hemangioma 31.4 TP53 KRT7 KRAS IDH1
8 cholangitis, primary sclerosing 31.3 KRT7 KRT19 AFP
9 bile duct cysts 31.3 KRT7 KRT19 KRAS AFP
10 papillary adenocarcinoma 31.2 TP53 KRT7 KRT19 KRAS
11 pancreatic ductal adenocarcinoma 31.2 TP53 MUC4 KRT19 KRAS
12 colorectal adenocarcinoma 31.1 TP53 KRT7 KRAS APC
13 signet ring cell adenocarcinoma 31.1 TP53 KRT7 KRAS
14 cavernous hemangioma 31.0 KRT7 KRT19 AFP
15 pancreatic adenocarcinoma 30.9 TP53 MUC4 KRT19 KRAS FGFR2 APC
16 angiosarcoma 30.9 TP53 KRT7 KRAS
17 adenofibroma 30.9 TP53 KRT7 KRT19
18 intrahepatic bile duct adenoma 30.9 KRT7 KRT19 AFP
19 bile duct cystadenocarcinoma 30.9 KRT7 AFP
20 thyroid tumor 30.9 TP53 KRAS FGFR2
21 rectum adenocarcinoma 30.9 TP53 KRT7 KRAS
22 appendix adenocarcinoma 30.8 KRT7 KRAS
23 mucinous adenocarcinoma 30.8 TP53 KRT7 KRT19 KRAS
24 carcinosarcoma 30.8 TP53 KRT7 KRAS
25 benign mesothelioma 30.7 KRT7 AFP
26 adenosquamous carcinoma 30.7 TP53 MUC4 KRT7 KRT19 KRAS
27 bile duct cancer 30.7 TP53 MUC4 MIR424 KRT7 KRT19 KRAS
28 fibrolamellar carcinoma 30.7 KRT7 KRT19 FGFR2 AFP
29 thyroid gland cancer 30.6 TP53 KRT7 KRT19 KRAS APC
30 ampulla of vater cancer 30.6 TP53 KRT7 KRAS
31 biliary tract benign neoplasm 30.6 TP53 KRT7 KRT19 KRAS AFP
32 hepatoblastoma 30.5 TUG1 TP53 KRT7 APC AFP
33 squamous cell carcinoma 30.5 TUG1 TP53 KRT7 KRT19 FGFR2 CCAT2
34 intrahepatic biliary papillomatosis 30.5 KRAS AFP
35 villous adenoma 30.5 TP53 KRAS APC
36 transverse colon cancer 30.5 KRT7 KRAS
37 wilms tumor 1 30.4 TP53 KRT7 KRAS AFP
38 bronchiolo-alveolar adenocarcinoma 30.4 MUC4 KRT7 KRAS
39 gallbladder cancer 30.4 TUG1 TP53 KRT7 KRT19 KRAS CCAT1
40 small intestine cancer 30.4 TP53 KRT7 KRAS
41 bile duct disease 30.4 TP53 MIR424 KRT7 KRT19 KRAS AFP
42 small cell carcinoma 30.4 TP53 KRT7 KRT19 KRAS
43 dysgerminoma 30.4 KRT7 FGFR2 AFP
44 gastric adenocarcinoma 30.3 TP53 MUC4 KRT7 KRAS IDH1 FGFR2
45 biliary tract disease 30.3 TP53 MIR424 KRT7 KRT19 KRAS AFP
46 gallbladder disease 30.3 TP53 KRT7 KRAS AFP
47 rectum cancer 30.3 MIR424 MIR214 KRAS APC
48 renal cell carcinoma, papillary, 1 30.2 TP53 MIR424 KRT7 KRT19
49 clear cell renal cell carcinoma 30.1 TUG1 TP53 KRT7 KRAS IDH1 CCAT2
50 osteogenic sarcoma 30.0 TUG1 TP53 CCAT2 CCAT1
51 endometrial cancer 29.9 TUG1 TP53 KRT7 KRAS FGFR2 CCAT1
52 lung squamous cell carcinoma 29.8 TUG1 TP53 KRT19 KRAS FGFR2 CCAT2
53 glioma 29.8 TP53 IDH2 IDH1 CCAT2 CCAT1
54 myeloma, multiple 29.7 TUG1 TP53 KRAS IDH2 IDH1 CCAT1
55 esophageal cancer 29.5 TP53 MUC4 MIR424 KRT19 KRAS FGFR2
56 leukemia, acute lymphoblastic 29.4 TP53 MIR424 MIR22 KRAS APC
57 renal cell carcinoma, nonpapillary 29.4 TUG1 TP53 MIR22 MIR214 KRT7 KRT19
58 lung cancer susceptibility 3 29.2 TUG1 TP53 MUC4 MIR376A1 KRT7 KRT19
59 bile duct adenocarcinoma 28.9 TP53 MIR424 MIR376A1 KRT7 KRT19 KRAS
60 bladder cancer 28.8 TUG1 TP53 MIR214 MIR127 KRT19 KRAS
61 gastrointestinal system disease 28.5 MIR424 MIR22 MIR214 MIR127 APC
62 gastric cancer 28.4 TUG1 TP53 MUC4 MIR22 MIR214 KRT19
63 gastrointestinal system cancer 28.1 MIR424 MIR22 MIR214 MIR127 APC
64 pancreas disease 28.0 TP53 MIR424 MIR22 MIR214 MIR127 KRAS
65 pancreatic cancer 27.8 TUG1 TP53 MUC4 MIR424 MIR376A1 MIR214
66 hepatocellular carcinoma 27.8 TUG1 TP53 MIR424 MIR22 MIR214 MIR127
67 colorectal cancer 27.3 TUG1 TP53 MUC4 MIR424 MIR22 MIR214
68 ovarian cancer 26.2 TUG1 TP53 MUC4 MIR424 MIR376A1 MIR22
69 lung cancer 25.4 TUG1 TP53 MUC4 MIR424 MIR376A1 MIR22
70 signet ring cell intrahepatic cholangiocarcinoma 12.5
71 convulsions, familial infantile, with paroxysmal choreoathetosis 10.9
72 liver cirrhosis 10.8
73 rare head and neck tumor 10.7 TP53 FGFR2
74 bile duct mucinous adenocarcinoma 10.7 TP53 MUC4
75 proliferating trichilemmal cyst 10.7 KRT7 KRT19
76 cholangitis 10.7
77 pancreatic foamy gland adenocarcinoma 10.7 TP53 KRT7
78 ampulla of vater neoplasm 10.7 KRAS APC
79 breast intraductal papillomatosis 10.7 IDH2 IDH1
80 nasal cavity adenocarcinoma 10.7 KRT7 KRAS
81 breast duct papilloma 10.7 IDH2 IDH1
82 rare adenocarcinoma of the breast 10.7 TP53 KRAS
83 hyperplastic polyposis syndrome 10.7 TP53 KRAS APC
84 breast papillomatosis 10.7 IDH2 IDH1
85 laryngeal neuroendocrine tumor 10.7 TP53 IDH1
86 urachal adenocarcinoma 10.7 KRAS AFP
87 periampullary adenoma 10.7 KRAS APC
88 enchondroma 10.7 IDH2 IDH1
89 apocrine adenoma 10.7 KRT7 KRAS
90 ovarian seromucinous carcinoma 10.7 TP53 KRT7
91 adult brain stem glioma 10.7 IDH2 IDH1
92 apocrine adenosis of breast 10.7 TP53 FGFR2
93 liver angiosarcoma 10.7 TP53 KRT19 KRAS
94 cytogenetically normal acute myeloid leukemia 10.7 IDH2 IDH1
95 vulvar apocrine adenocarcinoma 10.7 KRT7 KRT19
96 frontal lobe neoplasm 10.7 TP53 IDH1
97 vaginal tubulovillous adenoma 10.7 KRT7 KRAS
98 gallbladder leiomyosarcoma 10.7 KRT19 AFP
99 non-gestational ovarian choriocarcinoma 10.7 TP53 AFP
100 mucinous tubular and spindle renal cell carcinoma 10.7 MUC4 KRT7 KRT19
101 eccrine sweat gland cancer 10.7 TP53 KRT7 KRT19
102 sweat gland cancer 10.7 TP53 KRT7 KRT19
103 gallbladder benign neoplasm 10.7 TP53 KRT7 KRAS
104 myh-associated polyposis 10.7 KRAS APC
105 rete testis neoplasm 10.7 KRT7 AFP
106 sigmoid neoplasm 10.7 KRT7 KRAS
107 intracranial chondrosarcoma 10.7 IDH2 IDH1
108 anal canal adenocarcinoma 10.7 KRT7 KRT19
109 rete testis adenocarcinoma 10.7 KRT7 AFP
110 necrotizing sialometaplasia 10.7 TP53 KRT7
111 clear cell basal cell carcinoma 10.7 TP53 KRT7 KRT19
112 immature teratoma of ovary 10.7 KRAS AFP
113 colonic benign neoplasm 10.7 TP53 KRAS APC
114 endosalpingiosis 10.7 TP53 KRT7 KRAS
115 intrahepatic gall duct cancer 10.7 KRT7 KRT19
116 appendix disease 10.7 TP53 KRT7 KRAS
117 papillary adenoma 10.7 TP53 KRT7 KRAS
118 rectum neuroendocrine neoplasm 10.7 KRT7 AFP
119 appendix cancer 10.7 TP53 KRT7 KRAS
120 struma ovarii 10.7 KRT7 KRT19 KRAS
121 appendiceal neoplasm 10.6 KRT7 KRAS
122 periosteal chondrosarcoma 10.6 IDH2 IDH1
123 pancreatic acinar cell adenocarcinoma 10.6 KRT19 KRAS AFP
124 nasal cavity cancer 10.6 TP53 KRT7 KRAS
125 gemistocytic astrocytoma 10.6 TP53 IDH2 IDH1
126 adult teratoma 10.6 TP53 FGFR2 AFP
127 fibroma 10.6 KRT7 KRT19 KRAS
128 adult astrocytic tumour 10.6 TP53 IDH2 IDH1
129 basaloid squamous cell carcinoma 10.6 TP53 KRT7 KRT19
130 anus cancer 10.6 TP53 KRT7 KRAS
131 chondroblastic osteosarcoma 10.6 TP53 IDH2 IDH1
132 duodenum cancer 10.6 TP53 KRT7 KRAS
133 mixed oligodendroglioma-astrocytoma 10.6 TP53 IDH2 IDH1
134 acanthoma 10.6 TP53 KRT7 FGFR2
135 ovarian endodermal sinus tumor 10.6 KRT7 AFP
136 mixed glioma 10.6 TP53 IDH2 IDH1
137 bile duct mucoepidermoid carcinoma 10.6 MUC4 KRT7
138 epididymal neoplasm 10.6 KRT7 AFP
139 papillary serous adenocarcinoma 10.6 TP53 KRT7 KRAS
140 myxofibrosarcoma 10.6 TP53 MUC4 KRAS
141 intratubular embryonal carcinoma 10.6 TP53 KRT7 AFP
142 liver benign neoplasm 10.6 TP53 KRT19 AFP
143 renal pelvis adenocarcinoma 10.6 KRT7 KRT19 AFP
144 squamous cell bile duct carcinoma 10.6 KRT7 KRT19
145 respiratory system benign neoplasm 10.6 TP53 KRT7 KRAS
146 pseudomyxoma peritonei 10.6 TP53 KRT7 KRAS
147 lipoadenoma 10.6 KRT7 KRT19
148 papillary transitional carcinoma 10.6 TP53 KRT7
149 ovarian germ cell teratoma 10.6 KRT7 KRT19 AFP
150 oropharynx cancer 10.6 TP53 KRT7 APC
151 ovarian primitive germ cell tumor 10.6 KRT7 AFP
152 thymic carcinoma 10.6 TP53 KRT7 KRT19
153 fibrillary astrocytoma 10.6 TP53 IDH2 IDH1
154 ovarian benign neoplasm 10.6 TP53 KRT7 AFP
155 lymphangioma 10.6 TP53 KRAS APC
156 ovarian germ cell cancer 10.6 KRT7 KRT19 AFP
157 ameloblastoma 10.6 TP53 KRT19 KRAS
158 colonic lymphangioma 10.6 KRT7 AFP
159 hepatitis b 10.6
160 intraductal breast benign neoplasm 10.6 KRT7 IDH2 IDH1
161 brooke-spiegler syndrome 10.6 TP53 KRT7 KRT19
162 intraductal papilloma 10.6 KRT7 IDH2 IDH1
163 lung benign neoplasm 10.6 TP53 KRT7 KRAS
164 hidrocystoma 10.6 KRT7 KRT19
165 viral hepatitis 10.6
166 ovarian clear cell carcinoma 10.6 TP53 KRT7 KRAS
167 adult oligodendroglioma 10.6 IDH2 IDH1
168 acinar cell carcinoma 10.6 TP53 KRT7 AFP
169 brain stem glioma 10.6 TP53 IDH2 IDH1
170 giant cell glioblastoma 10.6 TP53 IDH2 IDH1
171 pilomyxoid astrocytoma 10.6 KRAS IDH2 IDH1
172 benign teratoma 10.6 TP53 KRT7 AFP
173 serous cystadenocarcinoma 10.6 TP53 KRT7 KRAS
174 pericardium cancer 10.6 KRT7 KRT19
175 intestinal benign neoplasm 10.6 TP53 KRAS APC
176 childhood oligodendroglioma 10.6 IDH2 IDH1
177 infratentorial cancer 10.6 TP53 IDH1 APC
178 syringocystadenoma papilliferum 10.6 KRT19 KRAS
179 paratesticular lipoma 10.6 KRT19 AFP
180 middle ear adenocarcinoma 10.6 KRT7 AFP
181 juxtacortical chondroma 10.6 IDH2 IDH1
182 lipoma of spermatic cord 10.6 KRT19 AFP
183 cervical adenocarcinoma 10.6 TP53 KRT7 KRAS
184 wolffian duct adenocarcinoma 10.6 TP53 KRT7 KRAS FGFR2
185 pre-malignant neoplasm 10.6 TP53 KRT7 KRT19 KRAS
186 gastrointestinal system benign neoplasm 10.6 TP53 KRT7 KRAS APC
187 cardiovascular organ benign neoplasm 10.6 TP53 KRAS APC AFP
188 pulmonary artery leiomyosarcoma 10.6 KRT7 KRT19
189 liver sarcoma 10.6 KRT7 AFP
190 mucoepidermoid carcinoma 10.6 TP53 MUC4 KRT7 KRT19
191 brain glioma 10.6 TP53 IDH2 IDH1
192 large cell acanthoma 10.6 TP53 KRT7
193 ovary adenocarcinoma 10.6 TP53 KRT7 KRAS
194 endometrial adenocarcinoma 10.6 TP53 KRT7 KRAS FGFR2
195 breast hemangioma 10.6 TP53 KRT7 IDH2 IDH1
196 glandular cystitis 10.6 TP53 KRT7
197 sclerosing hepatic carcinoma 10.6 KRT19 AFP
198 mature teratoma 10.6 TP53 KRT7 KRAS AFP
199 teratoma 10.6 TP53 KRT7 KRAS AFP
200 large cell carcinoma 10.6 KRT7 KRT19 KRAS
201 thoracic benign neoplasm 10.6 TP53 KRT7 IDH2 IDH1
202 mixed cell type cancer 10.6 TP53 KRT7 KRAS AFP
203 cystic teratoma 10.6 TP53 KRT7 KRAS AFP
204 breast benign neoplasm 10.6 TP53 KRT7 IDH2 IDH1
205 reproductive organ benign neoplasm 10.6 TP53 KRT7 KRAS AFP
206 myxoid liposarcoma 10.6 TP53 KRT19 FGFR2
207 central nervous system cancer 10.6 TP53 IDH2 IDH1 APC
208 suppression of tumorigenicity 12 10.5 TP53 KRT7 KRAS IDH1
209 ovarian mucinous neoplasm 10.5 KRT7 KRAS
210 essential thrombocythemia 10.5 TP53 KRAS IDH2 IDH1
211 tumor of exocrine pancreas 10.5 TP53 KRAS
212 eccrine acrospiroma 10.5 KRT7 KRT19
213 sclerosing cholangitis 10.5
214 biliary tract cancer 10.5
215 cystadenofibroma 10.5 KRT7 AFP
216 eccrine sweat gland neoplasm 10.5 KRT7 KRT19
217 colorectal adenoma 10.5 TP53 KRAS APC
218 limbal stem cell deficiency 10.5 MUC4 KRT19
219 liver leiomyosarcoma 10.5 KRT7 AFP
220 liver disease 10.5
221 adenoid cystic carcinoma 10.5 TP53 KRT7 KRT19 KRAS IDH1
222 ovarian serous carcinoma 10.5 TP53 MIR214 KRAS
223 eccrine papillary adenocarcinoma 10.5 KRT7 KRT19
224 hepatitis c virus 10.5
225 ovarian serous adenofibroma 10.4 TP53 KRT7
226 neutropenia 10.4
227 tubular adenocarcinoma 10.4
228 rare cancer of corpus uteri 10.4 TP53 KRAS FGFR2
229 cutaneous adenocystic carcinoma 10.4 KRT7 KRT19
230 obstructive jaundice 10.4
231 spinal cord oligodendroglioma 10.4 TP53 IDH1
232 cervix carcinoma 10.4 TP53 MIR214 APC
233 glioma susceptibility 1 10.4 TUG1 TP53 IDH2 IDH1
234 hepatitis c 10.4
235 hepatitis 10.4
236 rare tumor 10.4
237 bone sarcoma 10.4 TP53 MIR214 IDH2 IDH1
238 bile duct adenoma 10.4
239 in situ carcinoma 10.4
240 interval angle-closure glaucoma 10.3 IDH2 IDH1
241 bladder urothelial carcinoma 10.3 TUG1 TP53 KRT7 KRAS IDH1
242 retinal cancer 10.3 TP53 MIR214 APC
243 choledocholithiasis 10.3
244 cholestasis 10.3
245 autoimmune pancreatitis 10.3
246 nasal cavity olfactory neuroblastoma 10.3 KRT7 KRT19
247 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.3
248 portal hypertension 10.3
249 severe combined immunodeficiency 10.3
250 cholangiolocellular carcinoma 10.3
251 fatty liver disease 10.3
252 gallbladder disease 1 10.3
253 schistosoma mansoni infection, susceptibility/ 10.2
254 budd-chiari syndrome 10.2
255 cholelithiasis 10.2
256 cholecystolithiasis 10.2
257 clonorchiasis 10.2
258 schistosomiasis 10.2
259 lymphoepithelioma-like carcinoma 10.2
260 47,xyy 10.2
261 thyroid carcinoma 10.2
262 small cell cancer of the lung 10.2 TUG1 TP53 KRT7 KRT19 CCAT2
263 varicose veins 10.2
264 gastrointestinal stromal tumor 10.2
265 thrombosis 10.2
266 non-alcoholic fatty liver disease 10.2
267 non-alcoholic steatohepatitis 10.2
268 respiratory failure 10.2
269 portal vein thrombosis 10.2
270 acute cholangitis 10.2
271 thrombocytopenia 10.2
272 duodenal ulcer 10.2
273 papilloma 10.2
274 hemangioma of liver 10.2
275 bilirubin metabolic disorder 10.2
276 glioblastoma multiforme 10.2
277 gallbladder adenocarcinoma 10.2
278 b-cell lymphoma 10.2
279 combined hepatocellular carcinoma and cholangiocarcinoma 10.2
280 fibrosis of extraocular muscles, congenital, 1 10.2
281 mirizzi syndrome 10.2
282 grade iii astrocytoma 10.1 TP53 IDH2 IDH1
283 ovary epithelial cancer 10.1 TP53 MIR424 KRT7 KRAS APC
284 malignant ovarian surface epithelial-stromal neoplasm 10.1 TP53 MIR424 KRT7 KRAS APC
285 ovarian epithelial cancer 10.1 CPS1-IT1 CCAT2 CCAT1
286 breast cancer 10.1
287 hemochromatosis, type 1 10.1
288 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
289 body mass index quantitative trait locus 1 10.1
290 neutrophilic dermatosis, acute febrile 10.1
291 familial adenomatous polyposis 10.1
292 exanthem 10.1
293 diffuse large b-cell lymphoma 10.1
294 colitis 10.1
295 esophageal varix 10.1
296 hemosiderosis 10.1
297 porphyria 10.1
298 opisthorchiasis 10.1
299 alcohol use disorder 10.1
300 autoimmune hepatitis 10.1
301 splenic infarction 10.1
302 cystadenocarcinoma 10.1
303 hepatic tuberculosis 10.1
304 biliary papillomatosis 10.1
305 kidney disease 10.1
306 intestinal obstruction 10.1
307 ulcerative colitis 10.1
308 fascioliasis 10.1
309 chronic cholangitis 10.1
310 hypereosinophilic syndrome 10.1
311 hypoglycemia 10.1
312 congenital hepatic fibrosis 10.1
313 hepatic cystic hamartoma 10.1
314 splenomegaly 10.1
315 back pain 10.1
316 hypoxia 10.1
317 extracranial carotid artery aneurysm 10.1
318 acute liver failure 10.1
319 caroli disease, isolated 10.1
320 caroli disease 10.1
321 biliary atresia 10.1
322 pleural empyema 10.1
323 autoimmune disease 10.0
324 retinoblastoma 10.0
325 thrombophilia due to thrombin defect 10.0
326 ascaris lumbricoides infection 10.0
327 colon adenocarcinoma 10.0
328 ascaridiasis 10.0
329 familial retinoblastoma 10.0
330 pancreatitis 10.0
331 herpes simplex 10.0
332 48,xyyy 10.0
333 cytokine deficiency 10.0
334 retroperitoneal fibrosis 10.0
335 breast disease 10.0 TP53 MIR22 MIR214 KRT19
336 sarcoidosis 1 10.0
337 ataxia and polyneuropathy, adult-onset 10.0
338 diarrhea 10.0
339 crohn's disease 10.0
340 stomatitis 10.0
341 dysphagia 10.0
342 posttransplant acute limbic encephalitis 10.0
343 secondary sclerosing cholangitis 10.0
344 chordoma 10.0 TP53 KRT7 KRT19
345 hypophosphatemia 10.0
346 gastric ulcer 10.0
347 toxic shock syndrome 10.0
348 spindle cell carcinoma 10.0
349 alopecia 10.0
350 acute sensory ataxic neuropathy 10.0
351 acanthosis nigricans 9.9
352 neurofibromatosis, type ii 9.9
353 cat eye syndrome 9.9
354 epidermolysis bullosa with congenital localized absence of skin and deformity of nails 9.9
355 neurofibromatosis, type i 9.9
356 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.9
357 porphyria cutanea tarda 9.9
358 prostate cancer 9.9
359 thrombocytopenic purpura, autoimmune 9.9
360 thyroid cancer, nonmedullary, 1 9.9
361 lymphoma, hodgkin, classic 9.9
362 nijmegen breakage syndrome 9.9
363 proteasome-associated autoinflammatory syndrome 1 9.9
364 wiskott-aldrich syndrome 9.9
365 lymphoma, non-hodgkin, familial 9.9
366 nasopharyngeal carcinoma 9.9
367 mycobacterium tuberculosis 1 9.9
368 acute promyelocytic leukemia 9.9
369 fatty liver disease, nonalcoholic 1 9.9
370 pontine tegmental cap dysplasia 9.9
371 autoimmune lymphoproliferative syndrome, type v 9.9
372 pulmonary hypertension 9.9
373 erythema multiforme 9.9
374 hyperphosphatemia 9.9
375 visceral heterotaxy 9.9
376 inflammatory bowel disease 9.9
377 abdominal tuberculosis 9.9
378 autosomal recessive disease 9.9
379 inflammatory myofibroblastic tumor 9.9
380 uterine corpus endometrial carcinoma 9.9
381 lymphoma 9.9
382 ductal carcinoma in situ 9.9
383 childhood acute lymphocytic leukemia 9.9
384 polycystic kidney disease 9.9
385 igg4-related disease 9.9
386 dermatomyositis 9.9
387 asbestosis 9.9
388 hemiplegia 9.9
389 hemopericardium 9.9
390 cardiac tamponade 9.9
391 pericardial effusion 9.9
392 nephrotic syndrome 9.9
393 allergic hypersensitivity disease 9.9
394 primary biliary cirrhosis 9.9
395 leukemia 9.9
396 pancytopenia 9.9
397 hellp syndrome 9.9
398 megaesophagus 9.9
399 cutaneous porphyria 9.9
400 patent foramen ovale 9.9
401 alcoholic liver cirrhosis 9.9
402 pericholangitis 9.9
403 echinococcosis 9.9
404 panniculitis 9.9
405 vascular cancer 9.9
406 neuroendocrine carcinoma 9.9
407 malignant fibrous histiocytoma 9.9
408 melanoma 9.9
409 cholecystitis 9.9
410 constipation 9.9
411 ascending colon cancer 9.9
412 kidney cancer 9.9
413 cystadenoma 9.9
414 tic disorder 9.9
415 laryngeal squamous cell carcinoma 9.9
416 acute pancreatitis 9.9
417 glomerulonephritis 9.9
418 breast ductal carcinoma 9.9
419 papillary carcinoma 9.9
420 lipid metabolism disorder 9.9
421 embryonal carcinoma 9.9
422 purpura 9.9
423 extrahepatic bile duct adenocarcinoma 9.9
424 mucinous cystadenocarcinoma 9.9
425 lynch syndrome 9.9
426 gastritis 9.9
427 fibrous histiocytoma 9.9
428 sclerosing hemangioma 9.9
429 keratinizing squamous cell carcinoma 9.9
430 peritonitis 9.9
431 polycythemia 9.9
432 ileus 9.9
433 bullous pemphigoid 9.9
434 neurofibromatosis 9.9
435 autosomal dominant polycystic kidney disease 9.9
436 hepatopulmonary syndrome 9.9
437 amyloidosis 9.9
438 achalasia 9.9
439 diabetes mellitus 9.9
440 pulmonary embolism 9.9
441 encephalitis 9.9
442 toxocariasis 9.9
443 lymph node disease 9.9
444 heterotaxy 9.9
445 chromophil renal cell carcinoma 9.9
446 embryonal sarcoma 9.9
447 fibrillary glomerulonephritis 9.9
448 horseshoe kidney 9.9
449 left-sided gallbladder 9.9
450 limbic encephalitis 9.9
451 mast cell activation syndrome 9.9
452 pediatric acute-onset neuropsychiatric syndrome 9.9
453 supraglottic laryngeal cancer 9.9
454 hypotonia 9.9
455 paraneoplastic syndromes 9.9
456 rare parasitic disease 9.9
457 asbestos intoxication 9.9
458 rare hereditary hemochromatosis 9.9
459 igg4-related sclerosing cholangitis 9.9
460 glomerular disease 9.9
461 overgrowth syndrome 9.9
462 refractory anemia 9.9
463 hypercholesterolemia, familial, 1 9.9
464 triiodothyronine receptor auxiliary protein 9.9
465 ascites, chylous 9.9
466 cystic fibrosis 9.9
467 body mass index quantitative trait locus 11 9.9
468 wilms tumor 5 9.9
469 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.9
470 follicular lymphoma 9.9
471 endocarditis 9.9
472 hydronephrosis 9.9
473 pertussis 9.9
474 hepatitis a 9.9
475 thrombophlebitis 9.9
476 biliary dyskinesia 9.9
477 peptic ulcer disease 9.9
478 appendicitis 9.9
479 cryptogenic cirrhosis 9.9
480 rapidly involuting congenital hemangioma 9.9
481 polymyositis 9.8 MIR214 MIR127
482 burkitt lymphoma 9.8
483 lymphoma, mucosa-associated lymphoid type 9.8
484 tetralogy of fallot 9.8
485 graves disease 1 9.8
486 wilson disease 9.8
487 body mass index quantitative trait locus 9 9.8
488 body mass index quantitative trait locus 8 9.8
489 body mass index quantitative trait locus 4 9.8
490 body mass index quantitative trait locus 10 9.8
491 body mass index quantitative trait locus 7 9.8
492 myocardial infarction 9.8
493 human immunodeficiency virus type 1 9.8
494 body mass index quantitative trait locus 12 9.8
495 body mass index quantitative trait locus 14 9.8
496 alpha-1-antitrypsin deficiency 9.8
497 body mass index quantitative trait locus 18 9.8
498 melanoma, cutaneous malignant 10 9.8
499 body mass index quantitative trait locus 19 9.8
500 body mass index quantitative trait locus 20 9.8
501 deficiency anemia 9.8
502 hepatocellular adenoma 9.8
503 marantic endocarditis 9.8
504 bone disease 9.8
505 thalassemia 9.8
506 sialadenitis 9.8
507 bacterial infectious disease 9.8
508 microphthalmia 9.8
509 thrombotic thrombocytopenic purpura 9.8
510 iron deficiency anemia 9.8
511 gastroparesis 9.8
512 hepatic coma 9.8
513 typhoid fever 9.8
514 hyperparathyroidism 9.8
515 candidiasis 9.8
516 cryptosporidiosis 9.8
517 ocular melanoma 9.8
518 endodermal sinus tumor 9.8
519 leiomyosarcoma 9.8
520 neuroma 9.8
521 iron metabolism disease 9.8
522 granular cell tumor 9.8
523 acalculous cholecystitis 9.8
524 antiphospholipid syndrome 9.8
525 myelitis 9.8
526 vaccinia 9.8
527 fibrosarcoma 9.8
528 liposarcoma 9.8
529 duodenal obstruction 9.8
530 protein c deficiency 9.8
531 porokeratosis 9.8
532 myopathy 9.8
533 testicular yolk sac tumor 9.8
534 distal biliary tract carcinoma 9.8
535 lymphopenia 9.8
536 situs inversus 9.8
537 lupus erythematosus 9.8
538 liver inflammatory pseudotumor 9.8
539 krukenberg carcinoma 9.8
540 pulmonary emphysema 9.8
541 dextrocardia with situs inversus 9.8
542 hemangioendothelioma 9.8
543 pituitary tumors 9.8
544 pik3ca-related overgrowth syndrome 9.8
545 autosomal genetic disease 9.7 TP53 MIR22 MIR127 APC
546 male reproductive system disease 9.7 MIR424 MIR22 MIR214 APC
547 urinary system disease 9.7 MIR424 MIR22 MIR214 APC
548 male reproductive organ cancer 9.7 MIR424 MIR22 MIR214 APC
549 alcohol dependence 9.7
550 arteries, anomalies of 9.7
551 paragangliomas 4 9.7
552 exostoses, multiple, type i 9.7
553 congenital anomalies of kidney and urinary tract 2 9.7
554 yellow nail syndrome 9.7
555 melanoma, uveal 9.7
556 muir-torre syndrome 9.7
557 optic atrophy 1 9.7
558 peutz-jeghers syndrome 9.7
559 protoporphyria, erythropoietic, 1 9.7
560 thyroid cancer, nonmedullary, 2 9.7
561 ataxia-telangiectasia 9.7
562 hypouricemia, renal, 1 9.7
563 diabetes mellitus, type i 9.7
564 duodenal atresia 9.7
565 fanconi anemia, complementation group a 9.7
566 gaucher disease, type i 9.7
567 ocular motor apraxia 9.7
568 pancreatic agenesis 1 9.7
569 thymoma, familial 9.7
570 werner syndrome 9.7
571 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.7
572 tubulin, beta 9.7
573 hemophilia b 9.7
574 kearns-sayre syndrome 9.7
575 stroke, ischemic 9.7
576 cataract 3, multiple types 9.7
577 light fixation seizure syndrome 9.7
578 anorexia nervosa 9.7
579 lissencephaly 1 9.7
580 psoriatic arthritis 9.7
581 cavitary optic disc anomalies 9.7
582 beta-thalassemia 9.7
583 aspergillosis 9.7
584 accelerated tumor formation 9.7
585 bent bone dysplasia syndrome 9.7
586 prostate cancer, hereditary, 2 9.7
587 leptin deficiency or dysfunction 9.7
588 hyperlipoproteinemia, type iii 9.7
589 lipoprotein quantitative trait locus 9.7
590 angina pectoris 9.7
591 erysipeloid 9.7
592 cutaneous lupus erythematosus 9.7
593 brugada syndrome 9.7
594 intestinal schistosomiasis 9.7
595 marginal zone b-cell lymphoma 9.7
596 polycystic liver disease 9.7
597 sleep apnea 9.7
598 oral squamous cell carcinoma 9.7
599 gastrointestinal carcinoma 9.7
600 cd40 ligand deficiency 9.7
601 immunoglobulin alpha deficiency 9.7
602 cardiac arrest 9.7
603 inguinal hernia 9.7
604 hepatoid adenocarcinoma 9.7
605 progressive familial intrahepatic cholestasis 9.7
606 nodal marginal zone lymphoma 9.7
607 middle east respiratory syndrome 9.7
608 optic papillitis 9.7
609 microinvasive gastric cancer 9.7
610 pre-eclampsia 9.7
611 rickets 9.7
612 protein-losing enteropathy 9.7
613 abducens nerve disease 9.7
614 hydrocephalus 9.7
615 primary hyperparathyroidism 9.7
616 disseminated intravascular coagulation 9.7
617 vitamin k deficiency bleeding 9.7
618 adult respiratory distress syndrome 9.7
619 pyelonephritis 9.7
620 visual epilepsy 9.7
621 cryptococcosis 9.7
622 alveolar echinococcosis 9.7
623 goiter 9.7
624 hemolytic-uremic syndrome 9.7
625 paracoccidioidomycosis 9.7
626 telangiectasis 9.7
627 tolosa-hunt syndrome 9.7
628 acute cystitis 9.7
629 gout 9.7
630 brain cancer 9.7
631 hepatic encephalopathy 9.7
632 eclampsia 9.7
633 extrahepatic cholestasis 9.7
634 hepatic infarction 9.7
635 obstructive hydrocephalus 9.7
636 hypothyroidism 9.7
637 angioedema 9.7
638 lymphadenitis 9.7
639 keratosis 9.7
640 cystitis 9.7
641 neuroendocrine tumor 9.7
642 calcinosis 9.7
643 hyperuricemia 9.7
644 gaucher's disease 9.7
645 drug-induced hepatitis 9.7
646 granulomatous hepatitis 9.7
647 thrombophilia 9.7
648 sensory peripheral neuropathy 9.7
649 adenomyoma 9.7
650 transitional cell carcinoma 9.7
651 hemoglobinopathy 9.7
652 acute kidney failure 9.7
653 neurilemmoma 9.7
654 rhabdomyosarcoma 9.7
655 thymoma 9.7
656 mesenchymal cell neoplasm 9.7
657 palmoplantar keratosis 9.7
658 breast adenocarcinoma 9.7
659 pancreatic ductal carcinoma 9.7
660 choriocarcinoma 9.7
661 ovarian mucinous cystadenocarcinoma 9.7
662 bladder disease 9.7
663 lactic acidosis 9.7
664 pulmonary fibrosis 9.7
665 pancreatic cystadenoma 9.7
666 thyroid gland papillary carcinoma 9.7
667 linitis plastica 9.7
668 trophoblastic neoplasm 9.7
669 hyperglycemia 9.7
670 spindle cell sarcoma 9.7
671 intracranial embolism 9.7
672 seminoma 9.7
673 clear cell adenocarcinoma 9.7
674 hypokalemia 9.7
675 calciphylaxis 9.7
676 adenocarcinoma in situ 9.7
677 ureteral obstruction 9.7
678 hemoglobin e disease 9.7
679 ovarian serous cystadenocarcinoma 9.7
680 hemolytic anemia 9.7
681 acquired immunodeficiency syndrome 9.7
682 hypersplenism 9.7
683 peroneal nerve paralysis 9.7
684 parathyroid adenoma 9.7
685 muscular atrophy 9.7
686 extrahepatic biliary papillomatosis 9.7
687 paralytic ileus 9.7
688 localized scleroderma 9.7
689 arthritis 9.7
690 mucormycosis 9.7
691 lung disease 9.7
692 herpes zoster 9.7
693 measles 9.7
694 gastroduodenitis 9.7
695 vasculitis 9.7
696 myeloid leukemia 9.7
697 meningitis 9.7
698 dextrocardia 9.7
699 xanthogranulomatous cholecystitis 9.7
700 polyarteritis nodosa 9.7
701 hemophilia 9.7
702 atp8b1 deficiency 9.7
703 mutyh polyposis 9.7
704 cerebellar degeneration 9.7
705 cerulean cataract 9.7
706 chromosomal triplication 9.7
707 cryofibrinogenemia 9.7
708 distomatosis 9.7
709 fibromatosis 9.7
710 granulocytopenia 9.7
711 necrotizing autoimmune myopathy 9.7
712 nodular regenerative hyperplasia 9.7
713 paraneoplastic cerebellar degeneration 9.7
714 rosai-dorfman disease 9.7
715 urachal cancer 9.7
716 aneurysm 9.7
717 encephalopathy 9.7
718 extrapontine myelinolysis 9.7
719 seizure disorder 9.7
720 subacute cutaneous lupus erythematosus 9.7
721 systemic autoimmune disease 9.7
722 glial tumor 9.7
723 autoimmune pancreatitis type 1 9.7
724 familial intrahepatic cholestasis 9.7
725 patent urachus 9.7
726 argyria 9.7
727 spinal disease 9.6 TP53 MIR376A1 MIR127 IDH2 IDH1
728 cell type benign neoplasm 9.6 TP53 MIR22 MIR127 KRT7 KRAS APC
729 uterine anomalies 9.5 TP53 MIR22 MIR214 MIR127 APC
730 nemaline myopathy 9.5 MIR376A1 MIR214 MIR127
731 nervous system disease 9.5 MIR22 MIR214 MIR127 APC
732 lymphatic system cancer 9.4 TP53 MIR424 MIR214 MIR127 APC
733 lymphatic system disease 9.4 TP53 MIR424 MIR214 MIR127 APC
734 squamous cell carcinoma, head and neck 9.4 TP53 MIR424 MIR22 MIR214 KRT19 KRAS
735 connective tissue cancer 9.4 TP53 MIR376A1 MIR214 MIR127 IDH2 IDH1
736 muscular dystrophy, duchenne type 9.2 MIR376A1 MIR22 MIR214 MIR127
737 large intestine cancer 9.1 MIR424 MIR22 MIR214 MIR127 APC
738 endocrine gland cancer 9.1 MIR424 MIR22 MIR214 MIR127 APC
739 female reproductive system disease 9.1 MIR424 MIR22 MIR214 MIR127 APC
740 reproductive system disease 9.1 MIR424 MIR22 MIR214 MIR127 APC
741 thoracic cancer 9.1 MIR424 MIR22 MIR214 MIR127 APC
742 respiratory system disease 9.1 MIR424 MIR22 MIR214 MIR127
743 cervix disease 9.0 TP53 MIR424 MIR22 MIR214 MIR127 APC
744 immune system disease 9.0 TP53 MIR424 MIR22 MIR214 MIR127 APC
745 colonic disease 9.0 TP53 MIR424 MIR22 MIR214 MIR127 KRAS
746 endocrine system disease 9.0 TP53 MIR424 MIR22 MIR214 MIR127 KRAS
747 intestinal disease 9.0 TP53 MIR424 MIR22 MIR214 MIR127 KRAS
748 cervical cancer 8.7 TUG1 TP53 MIR424 MIR214 MIR127 KRT19
749 hematologic cancer 8.6 TP53 MIR424 MIR376A1 MIR22 MIR214 MIR127
750 leukemia, acute myeloid 8.3 TUG1 TP53 MIR424 MIR376A1 MIR22 MIR127

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26 (showing 11, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.4 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.4 APC
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.4 AFP APC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.4 APC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.4 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.4 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.4 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.4 APC
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 9.4 APC
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 AFP

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP APC FGFR2 IDH2 KRAS KRT19

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 300, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Etomidate Approved Phase 4 33125-97-2 36339 667484
5 Anesthetics, Inhalation Phase 4
6 Cyclooxygenase 2 Inhibitors Phase 4
7 Cyclooxygenase Inhibitors Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9 Platelet Aggregation Inhibitors Phase 4
10
Bismuth Phase 4 7440-69-9 16682734 105143
11 Ulipristal acetate Phase 4 126784-99-4
12 Omega 3 Fatty Acid Phase 4
13 Narcotics Phase 4
14 Hypnotics and Sedatives Phase 4
15 Anesthetics, General Phase 4
16 Analgesics Phase 4
17 Analgesics, Opioid Phase 4
18 Anesthetics, Intravenous Phase 4
19 Anti-Anxiety Agents Phase 4
20 GABA Modulators Phase 4
21
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
22
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
23
nivolumab Approved Phase 3 946414-94-4
24
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
26
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
27
Ipilimumab Approved Phase 3 477202-00-9
28
Simvastatin Approved Phase 3 79902-63-9 54454
29
Gemcitabine Approved Phase 3 95058-81-4 60750
30
Fluorouracil Approved Phase 3 51-21-8 3385
31
leucovorin Approved Phase 3 58-05-9 6006 143
32
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
33
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
34
Citalopram Approved Phase 3 59729-33-8 2771
35
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37 Hematinics Phase 3
38 Emetics Phase 3
39 Anthelmintics Phase 3
40 Antiparasitic Agents Phase 3
41 Pharmaceutical Solutions Phase 3
42 Calcium, Dietary Phase 2, Phase 3
43 Folfirinox Phase 2, Phase 3
44 Hypolipidemic Agents Phase 3
45 Anticholesteremic Agents Phase 3
46 Lipid Regulating Agents Phase 3
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
48 Trace Elements Phase 3
49 Micronutrients Phase 3
50 Vitamins Phase 3
51 Antidotes Phase 3
52 Vitamin B Complex Phase 3
53 Nutrients Phase 3
54 Folate Phase 3
55 Protective Agents Phase 3
56 Vitamin B9 Phase 3
57 Hematoporphyrin Derivative Phase 3
58 Neurotransmitter Agents Phase 3
59 Cola Phase 3
60 Hematoporphyrins Phase 3
61 Psychotropic Drugs Phase 3
62 Antidepressive Agents Phase 3
63 Parasympatholytics Phase 3
64 Cholinergic Agents Phase 3
65 Muscarinic Antagonists Phase 3
66 Serotonin Uptake Inhibitors Phase 3
67 Antiparkinson Agents Phase 3
68 Cholinergic Antagonists Phase 3
69
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
70
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
71
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
72
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
73
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
74
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
75
Trametinib Approved Phase 2 871700-17-3 11707110
76
Lenograstim Approved, Investigational Phase 2 135968-09-1
77
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
78
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
79
Adenosine Approved, Investigational Phase 2 58-61-7 60961
80
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
81
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
82
Hydroxyurea Approved Phase 2 127-07-1 3657
83
Pemetrexed Approved, Investigational Phase 1, Phase 2 137281-23-3, 150399-23-8 60843 446556
84
Fosaprepitant Approved Phase 2 172673-20-0 219090
85
Aprepitant Approved, Investigational Phase 2 170729-80-3 6918365 151165
86
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
87
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
88
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
89
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
90
ramucirumab Approved, Investigational Phase 2 947687-13-0
91
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
92
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
93
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
94
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
95
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
96
Temoporfin Approved, Investigational Phase 2 122341-38-2
97
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
98
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
99
Hydroxychloroquine Approved Phase 2 118-42-3 3652
100
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
101
Tinzaparin Approved Phase 2 9041-08-1, 9005-49-6 25244225
102
Dalteparin Approved Phase 2 9005-49-6
103
Apixaban Approved Phase 2 503612-47-3 10182969
104
Rivaroxaban Approved Phase 2 366789-02-8
105
Vinblastine Approved Phase 1, Phase 2 865-21-4 241903 13342
106
Colchicine Approved Phase 2 64-86-8 2833 6167
107
Mesna Approved, Investigational Phase 2 3375-50-6 598